United Therapeutics (UTHR) Short-term Investments (2009 - 2026)

United Therapeutics has disclosed Short-term Investments across 18 years of filings, most recently posting $874.0 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $874.0 million, down 38.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $874.0 million (down 38.51% YoY), and the FY2025 annual result was $1.4 billion, down 13.16% from the prior year.
• Short-term Investments came in at $874.0 million for Q1 2026 at United Therapeutics, down from $1.4 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $1.9 billion in Q4 2022 to a low of $874.0 million in Q1 2026.
• The 5-year median for Short-term Investments is $1.6 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Short-term Investments soared 81.24% in 2022 and tumbled 38.51% in 2026, its largest moves.
• United Therapeutics' Short-term Investments stood at $1.9 billion in 2022, then dropped by 4.85% to $1.8 billion in 2023, then slipped by 12.12% to $1.6 billion in 2024, then slipped by 13.16% to $1.4 billion in 2025, then plunged by 35.89% to $874.0 million in 2026.
• The last three Short-term Investments figures came in at $874.0 million (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.